We are pleased to announce that New Horizon Health Limited (6606.HK, “New Horizon Health”), a VMS invested company, has been selected to become a constituent stock of the Hang Seng Composite Index. In addition, New Horizon Health will also be added to the following benchmark and thematic indexes, with all these changes taking effect on June 7, 2021.

• Hang Seng Large-Mid Cap (Investable) Index
• Hang Seng Healthcare Index
• Hang Seng Stock Connect Hong Kong Index
• Hang Seng Stock Connect Hong Kong MidCap & SmallCap Index
• Hang Seng SCHK Mainland China Companies Index
• Hang Seng SCHK ex-AH Companies Index
• Hang Seng Hong Kong-Listed Biotech Index

Founded in 2015, New Horizon Health is a cancer screening market leader, focusing on the design, development and commercialization of cancer screening tests. The company’s vision is to prevent and cure cancer by screening and early detection.

VMS led its series C round of financing in 2019 and later participated in series D in 2020. New Horizon Health was successfully listed on the Hong Kong Stock Exchange at HKD 26.6/share on February 5, 2021. Its share price has skyrocketed to close at HKD 68.35/share as of May 21, 2021. The strong share price performance is an indication that the value of New Horizon Health is well recognized by the market.

If you would like to hear the latest updates on the Firm and the Fund, please feel free to contact our Investor Relations team at IR@VMSIG.COM.